Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tandutinib in Androgen-Independent Prostate Cancer With Bone Metastases
NCT00390468Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2006
- Primary completion
- Nov 2009
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of tandutinib in prostate cancer (PCa), sponsored by National Cancer Institute. Started Oct 2006; status: completed.
02
Drugs
tandutinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00390468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00390468.